Type 2 Diabetes: Symptoms, Diagnosis & NHS Treatment

Type 2 Diabetes: Symptoms, Diagnosis & NHS Treatment

Type 2 diabetes is a chronic metabolic condition in which the body either does not produce enough insulin or does not use insulin effectively, resulting in raised blood glucose levels. It affects over 4.3 million people in the UK — and an estimated 1 million more remain undiagnosed. Type 2 diabetes is largely preventable and, in some cases, can be put into remission with significant lifestyle change or weight loss.

Key Facts

  • Over 4.3 million people in the UK have been diagnosed with diabetes — approximately 90% have type 2
  • An estimated 13.6 million people in the UK are at increased risk of developing type 2 diabetes
  • Type 2 diabetes is strongly associated with overweight, obesity, and physical inactivity
  • HbA1c is the primary diagnostic and monitoring blood test (diagnostic threshold: 48 mmol/mol)
  • NICE guideline NG28 governs NHS treatment; first-line drug treatment is metformin
  • Remission is achievable in some people through sustained weight loss of 10–15 kg or more

What Is Type 2 Diabetes?

Type 2 diabetes is characterised by insulin resistance — cells in the liver, muscle, and fat tissue become less responsive to insulin — combined with progressive beta-cell dysfunction, meaning the pancreas gradually loses its ability to produce sufficient insulin to overcome the resistance. The result is chronically elevated blood glucose (hyperglycaemia), which damages blood vessels and nerves throughout the body over time.

Unlike type 1 diabetes, which is an autoimmune condition causing near-total destruction of insulin-producing beta cells, type 2 diabetes develops gradually, typically over years. It is strongly associated with metabolic risk factors, particularly central obesity, physical inactivity, unhealthy diet, and increasing age. Genetic factors also play a role — having a first-degree relative with type 2 diabetes significantly increases risk.

Risk Factors for Type 2 Diabetes

Major risk factors include: overweight or obesity (particularly central/abdominal adiposity — waist circumference above 88 cm in women or above 102 cm in men); physical inactivity; family history of type 2 diabetes; age above 40 (or above 25 in South Asian and Black African/Caribbean populations, who are at higher risk at younger ages and lower BMI); previous gestational diabetes; polycystic ovary syndrome (PCOS); ethnicity (South Asian, Black African/Caribbean, and Middle Eastern people have 2–4 times higher risk); impaired glucose regulation or prediabetes (HbA1c 42–47 mmol/mol); and certain medications including long-term corticosteroids, antipsychotics, and HIV antiretroviral agents.

Symptoms of Type 2 Diabetes

Many people with type 2 diabetes have no symptoms initially — the condition is often discovered incidentally on blood tests. When symptoms do occur, they include: increased thirst (polydipsia); frequent urination (polyuria), particularly at night (nocturia); fatigue and lack of energy; blurred vision; slow-healing wounds or recurrent infections (especially urinary tract infections or thrush); unexplained weight loss (less common than in type 1); tingling or numbness in hands and feet (suggesting early neuropathy); and genital itching.

Diagnosing Type 2 Diabetes

Diagnosis is based on blood glucose criteria. HbA1c (glycated haemoglobin) is the preferred diagnostic test in the UK, as it reflects average blood glucose over the preceding 2–3 months. An HbA1c of 48 mmol/mol (6.5%) or above on two separate occasions (or once if symptomatic) confirms a diagnosis of diabetes. In symptomatic individuals, a single fasting plasma glucose of 7.0 mmol/L or above, or a random plasma glucose of 11.1 mmol/L or above, is also diagnostic.

Prediabetes is defined as HbA1c 42–47 mmol/mol (6.0–6.4%) or impaired fasting glucose (6.1–6.9 mmol/L). People with prediabetes have a significantly elevated risk of progressing to type 2 diabetes — but structured lifestyle intervention can prevent or delay progression by up to 58% (as demonstrated in the Diabetes Prevention Programme). The NHS Diabetes Prevention Programme (NHS DPP) — a free, evidence-based structured lifestyle programme — is offered to all people with prediabetes in England.

NHS Treatment (NICE NG28)

NICE guideline NG28 (Type 2 Diabetes in Adults, 2015, updated 2022) governs NHS management. The individual HbA1c target is agreed collaboratively — typically 48 mmol/mol (6.5%) for most people on lifestyle/metformin, or 53 mmol/mol (7.0%) for those on medication that can cause hypoglycaemia or where a lower target is not safe or appropriate. The overarching goals are to reduce symptoms, prevent complications, and reduce cardiovascular risk.

Lifestyle modification: Diet and physical activity remain the foundation of type 2 diabetes management. NHS guidance recommends reducing refined carbohydrates and sugar, increasing vegetables and fibre, limiting saturated fat, controlling calorie intake for weight management, and engaging in at least 150 minutes of moderate-intensity physical activity per week. Structured education programmes such as DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) are offered to all newly diagnosed patients.

Metformin: First-line drug treatment for type 2 diabetes. Metformin reduces hepatic glucose production and improves insulin sensitivity. It does not cause weight gain or hypoglycaemia. Gastrointestinal side effects (nausea, diarrhoea) are common, particularly on initiation — starting with a low dose and slow titration reduces this. Modified-release metformin is better tolerated. Metformin is contraindicated in severe renal impairment (eGFR below 30 mL/min/1.73m²) and should be used with caution when eGFR is 30–45.

SGLT2 inhibitors (gliflozins): Dapagliflozin, empagliflozin, and canagliflozin promote urinary glucose excretion independently of insulin. They reduce HbA1c, cause modest weight loss, lower blood pressure, and have been shown in major cardiovascular outcome trials (EMPA-REG, CANVAS, DECLARE-TIMI, CREDENCE) to significantly reduce cardiovascular events, hospitalisation for heart failure, and progression of diabetic kidney disease. NICE now recommends an SGLT2 inhibitor with proven cardiovascular benefit as first intensification step for people with established cardiovascular disease, heart failure, or CKD.

GLP-1 receptor agonists: Injectable agents (semaglutide, liraglutide, dulaglutide, exenatide) stimulate insulin secretion in a glucose-dependent manner, suppress glucagon, slow gastric emptying, and reduce appetite. They produce significant weight loss (semaglutide — Ozempic/Rybelsus — produces the greatest weight loss of approved agents). Oral semaglutide (Rybelsus) is available for those who prefer an oral option. GLP-1 RAs have proven cardiovascular and renal benefits in people with type 2 diabetes and established CVD. They are recommended by NICE as an option alongside metformin when further intensification is needed, particularly in those with obesity or cardiovascular disease.

DPP-4 inhibitors (gliptins): Sitagliptin, alogliptin, saxagliptin, and vildagliptin are weight-neutral oral agents with a low hypoglycaemia risk. They are less effective at lowering HbA1c than SGLT2 inhibitors or GLP-1 RAs and have neutral cardiovascular effects. They are a useful option when other agents are not suitable.

Sulphonylureas (e.g., gliclazide, glipizide): Stimulate insulin secretion regardless of glucose level. Effective at lowering HbA1c but associated with weight gain and hypoglycaemia risk. Used less frequently as first intensification given availability of SGLT2 inhibitors and GLP-1 RAs.

Insulin: Required when oral/injectable non-insulin therapies no longer achieve glycaemic targets. Various insulin regimens are used — basal insulin (e.g., insulin glargine, insulin detemir) is usually the first insulin started. Insulin causes weight gain and hypoglycaemia — these risks must be managed with dose titration, dietary advice, and patient education.

Preventing Diabetes Complications

Chronic hyperglycaemia damages blood vessels and nerves throughout the body. Microvascular complications include diabetic retinopathy (a leading cause of blindness in working-age adults in the UK); diabetic nephropathy (a leading cause of end-stage renal failure); and diabetic peripheral neuropathy (causing numbness, pain, and foot complications). Macrovascular complications include coronary artery disease, stroke, and peripheral arterial disease — accounting for the majority of premature mortality in type 2 diabetes.

All people with type 2 diabetes should receive annual reviews covering: HbA1c; blood pressure (target below 140/80 mmHg, or below 130/80 mmHg with existing CVD or CKD); lipids (statin therapy recommended for most people over 40 with type 2 diabetes — atorvastatin 20 mg first-line); eGFR and urine albumin-to-creatinine ratio (ACR); annual retinal screening (digital fundus photography); annual foot examination (to assess neuropathy and vascular status); and body weight and BMI.

Diabetes Remission

Type 2 diabetes can go into remission — defined as HbA1c below 48 mmol/mol maintained for at least 3 months without diabetes medication. Remission is most achievable through sustained substantial weight loss (typically 10–15 kg or more). The DiRECT trial demonstrated that 46% of participants achieved remission at 12 months with a structured low-calorie diet (800 kcal/day for 3–5 months) and lifestyle support. NHS low-calorie diet programmes (NHS LCD pilot) are available in some areas. Bariatric surgery can also produce remission in people with severe obesity and type 2 diabetes.

⚠️ Signs of Diabetic Emergencies

Seek emergency help (call 999 or go to A&E) for: very low blood glucose (hypoglycaemia) with confusion, seizure, or loss of consciousness; very high blood glucose with vomiting, abdominal pain, and rapid breathing (possible diabetic ketoacidosis — DKA, which can occur in type 2 diabetes, especially in people of African or Caribbean descent or on SGLT2 inhibitors); or signs of hyperosmolar hyperglycaemic state (HHS) — extreme thirst, drowsiness, confusion in the context of very high blood glucose. DKA and HHS are life-threatening emergencies.

ℹ️ Foot Care in Diabetes

Diabetic foot disease is a leading cause of non-traumatic lower limb amputation in the UK. Peripheral neuropathy and peripheral arterial disease together impair wound healing and increase infection risk. All people with diabetes should receive annual foot checks, be taught daily foot inspection, and know the warning signs of diabetic foot problems: redness, swelling, warmth, new ulcers, or changes in sensation. Any new foot wound or ulcer should be assessed within 24 hours by a healthcare professional.

Related Conditions

Frequently Asked Questions

What is the difference between type 1 and type 2 diabetes?

Type 1 diabetes is an autoimmune condition in which the immune system destroys the insulin-producing beta cells of the pancreas, causing near-total insulin deficiency. It requires lifelong insulin replacement and usually develops in childhood or young adulthood. Type 2 diabetes is characterised by insulin resistance and progressive beta-cell dysfunction; it develops gradually, is strongly associated with lifestyle and metabolic factors, and can initially be managed with lifestyle changes and oral medications — though many people eventually require insulin.

Can type 2 diabetes be reversed?

Type 2 diabetes can go into remission — sustained weight loss of 10–15 kg or more achieves remission in a significant proportion of people with early or recent-onset type 2 diabetes. Remission means HbA1c below 48 mmol/mol without diabetes medication for at least 3 months. However, remission requires ongoing lifestyle maintenance — if weight is regained, blood glucose typically rises again. The longer someone has had diabetes and the more beta-cell function lost, the less likely remission is, but improvement is still achievable.

What foods should I avoid with type 2 diabetes?

There is no single “diabetes diet”, but general principles include: reducing free sugars (sugary drinks, sweets, cakes, biscuits); reducing refined carbohydrates (white bread, white rice, white pasta); avoiding very large portions of starchy foods; and limiting saturated fat and processed foods. Foods with a lower glycaemic index (wholegrains, legumes, most vegetables) produce a more gradual rise in blood glucose. Diabetes UK and the NHS provide evidence-based dietary guidance, and referral to a dietitian is recommended for all newly diagnosed patients.

What is HbA1c and what does my result mean?

HbA1c (glycated haemoglobin) measures the average blood glucose level over the preceding 2–3 months. It is expressed in mmol/mol: below 42 mmol/mol is normal; 42–47 mmol/mol is prediabetes; 48 mmol/mol or above indicates diabetes. For people already diagnosed with type 2 diabetes, the target is typically 48 mmol/mol (6.5%) if on lifestyle treatment or metformin alone, or 53 mmol/mol (7.0%) for most others. Higher targets may be appropriate for older people or those with complex needs where tighter control carries hypoglycaemia risk.

Am I entitled to free prescriptions for diabetes?

In England, people with diabetes requiring insulin or other medication are entitled to free NHS prescriptions via a Medical Exemption Certificate (Medex). Those who do not require insulin-based medication may not automatically qualify, though many qualify through other exemptions (age, low income). Blood glucose monitoring strips are available on NHS prescription for people on insulin or certain other medications. Contact your GP or diabetes nurse for further guidance on entitlements.